Aptevo Therapeutics Inc

NASDAQ:APVOUnited States

NASDAQ FSI:D. Deficient (Issuer failed to meet continued listing requirements)

Aptevo Therapeutics Inc. is a clinical-stage biotechnology company. It is focused on developing novel immunotherapy candidates for the treatment of different forms of cancer. It has developed two versatile and enabling platform technologies for rational design of precision immune modulatory drugs. Its lead clinical candidates, APVO436 and ALG.APV-527, and preclinical candidates, APVO603 and APVO711, are developed using its ADAPTIR modular protein technology platform. Its preclinical candidate APVO442 is developed using its ADAPTIR-FLEX modular protein technology platform. APVO436 is a bispecific ADAPTIR that is designed to engage CD3 and CD123 to redirect T-cells to destroy leukemia cells expressing the target CD123 molecule on their surface. ALG.APV-527 is a novel investigational bispecific ADAPTIR candidate. APVO603 is a preclinical dual agonist bispecific ADAPTIR candidate designed to simultaneously target 4-1BB (CD137) and OX40 (CD134), both members of the TNF-receptor family.

Contact Information

Headquarters

2401 4th Ave Ste 1050SEATTLE, WA, United States 98121-3460

Phone

206-838-0500

Fax

206-838-0503

Executives

Independent Chairman of the Board

John Niederhuber

President, Chief Executive Officer, Director

Marvin White

Chief Financial Officer, Senior Vice President

Daphne Taylor

Chief Operating Officer, Executive Vice President

Jeffrey Lamothe

Senior Vice President, General Counsel, Business Development and Corporate Affairs

So Young Kwon